US5096715A
(en)
*
|
1989-11-20 |
1992-03-17 |
Alko Ltd. |
Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
|
US5028612A
(en)
*
|
1990-03-22 |
1991-07-02 |
Hillel Glover |
Method for treating emotional numbness
|
US5013740A
(en)
*
|
1990-03-22 |
1991-05-07 |
Hillel Glover |
Method for treating emotional numbness and coma
|
US5086058A
(en)
*
|
1990-06-04 |
1992-02-04 |
Alko Ltd. |
Method for treating alcoholism with nalmefene
|
US5352680A
(en)
*
|
1992-07-15 |
1994-10-04 |
Regents Of The University Of Minnesota |
Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
|
US6096756A
(en)
*
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US5580876A
(en)
*
|
1992-09-21 |
1996-12-03 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
USRE36547E
(en)
*
|
1992-09-21 |
2000-02-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
|
US5298622A
(en)
*
|
1993-05-12 |
1994-03-29 |
Regents Of The University Of Minnesota |
Spiroindane opiate analogs
|
US5457208A
(en)
|
1993-06-21 |
1995-10-10 |
Regents Of The University Of Minnesota |
Kappa opioid receptor antagonists
|
US5587381A
(en)
*
|
1995-03-27 |
1996-12-24 |
Sinclair; John D. |
Method for terminating methadone maintenance through extinction of the opiate-taking responses
|
US6001848A
(en)
*
|
1996-03-25 |
1999-12-14 |
The Regents Of The University Of California |
Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
|
US5878750A
(en)
*
|
1996-11-14 |
1999-03-09 |
Clemens; Anton H. |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
US6203813B1
(en)
|
1997-01-13 |
2001-03-20 |
Lance L. Gooberman |
Pharmaceutical delivery device and method of preparation therefor
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
SI1685839T1
(sl)
|
1997-12-22 |
2013-08-30 |
Euro-Celtique S.A. |
Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
|
TR200001828T2
(tr)
|
1997-12-22 |
2000-11-21 |
Euro-Celtique, S.A. |
Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
|
AU1807401A
(en)
*
|
1999-11-30 |
2001-06-12 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
NZ520554A
(en)
|
2000-02-08 |
2005-08-26 |
Euro Celtique S |
Tamper-resistant oral opioid agonist formulations
|
US20040024004A1
(en)
*
|
2001-05-04 |
2004-02-05 |
Sherman Barry M. |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
|
US6262062B1
(en)
|
2000-08-15 |
2001-07-17 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
US6528520B2
(en)
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
US6846831B2
(en)
|
2000-08-15 |
2005-01-25 |
Cpd, Llc |
Method of treating the syndrome of lipodystrophy
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
CN1273075C
(zh)
*
|
2001-07-13 |
2006-09-06 |
爱科来株式会社 |
分析用具、具备分析用具的浓度测定装置用的穿刺元件一体化安装体及体液采取用具
|
DK1416842T3
(da)
|
2001-07-18 |
2009-03-16 |
Euro Celtique Sa |
Farmaceutiske kombinationer af oxycodon og naloxon
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030153590A1
(en)
*
|
2001-08-14 |
2003-08-14 |
Oy Contral Pharma Ltd |
Method of treating alcoholism or alcohol abuse
|
WO2003037313A2
(en)
*
|
2001-10-31 |
2003-05-08 |
Recovery Pharmaceuticals, Inc. |
Methods for the treatment of addiction
|
KR20040098050A
(ko)
|
2002-04-05 |
2004-11-18 |
유로-셀띠끄 소시에떼 아노님 |
옥시코돈 및 날록손을 포함하는 약제학적 제제
|
WO2003101358A1
(en)
*
|
2002-05-31 |
2003-12-11 |
Titan Pharmaceuticals, Inc. |
Implantable polymeric device for sustained release of buprenorphine
|
PT1551372T
(pt)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
WO2004078178A1
(en)
*
|
2003-03-03 |
2004-09-16 |
Markus Heilig |
Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
|
DE602004031512D1
(de)
|
2003-03-31 |
2011-04-07 |
Titan Pharmaceuticals Inc |
Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
CA2522471A1
(en)
*
|
2003-04-14 |
2004-10-28 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
JP2007502866A
(ja)
*
|
2003-05-30 |
2007-02-15 |
タイタン ファーマシューティカルズ インコーポレイテッド |
ナルメフェンの持続的放出のための移植可能ポリマー装置
|
US20060009478A1
(en)
*
|
2003-10-15 |
2006-01-12 |
Nadav Friedmann |
Methods for the treatment of back pain
|
US20050245541A1
(en)
*
|
2004-03-19 |
2005-11-03 |
Elliot Ehrich |
Methods for treating alcoholism
|
US20050245461A1
(en)
*
|
2004-03-19 |
2005-11-03 |
Elliot Ehrich |
Methods for treating alcoholism
|
US7919499B2
(en)
*
|
2004-04-22 |
2011-04-05 |
Alkermes, Inc. |
Naltrexone long acting formulations and methods of use
|
EP1604666A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
US7910599B2
(en)
|
2005-01-10 |
2011-03-22 |
John David Sinclair |
Method for treating eating disorders by selective extinction with transdermal naloxone
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
US20070259939A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Accelerated Technologies |
Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
|
US8158156B2
(en)
|
2006-06-19 |
2012-04-17 |
Alpharma Pharmaceuticals, Llc |
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
|
EP1897543A1
(de)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine-Waffel zur Substitutionstherapie
|
ES2618500T3
(es)
|
2006-10-20 |
2017-06-21 |
Neurendo Pharma, Llc |
Método para restaurar el efecto incretina
|
FI20070705L
(fi)
|
2007-09-14 |
2009-06-02 |
Biohit Oyj |
Asetaldehydin sitominen suussa ja mahalaukussa
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
EP2405915B1
(de)
|
2009-03-10 |
2018-10-24 |
Euro-Celtique S.A. |
Unmittelbare freisetzung pharmazeutischer zusammensetzungen mit oxycodon und naloxon
|
US8939943B2
(en)
|
2011-01-26 |
2015-01-27 |
Kaleo, Inc. |
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
|
US8627816B2
(en)
|
2011-02-28 |
2014-01-14 |
Intelliject, Inc. |
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
MA39956A
(fr)
*
|
2014-05-06 |
2015-11-12 |
Purdue Pharma Lp |
Analogues du benzomorphane et leur utilisation
|
US9517307B2
(en)
|
2014-07-18 |
2016-12-13 |
Kaleo, Inc. |
Devices and methods for delivering opioid antagonists including formulations for naloxone
|
WO2016073615A1
(en)
|
2014-11-07 |
2016-05-12 |
Regents Of The University Of Minnesota |
Salts and compositions useful for treating disease
|
MX2018015985A
(es)
*
|
2016-06-24 |
2019-09-13 |
Opiant Pharmaceuticals Inc |
Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.
|
WO2018093666A1
(en)
|
2016-11-18 |
2018-05-24 |
Opiant Pharmaceuticals, Inc. |
Compositions and methods for the treatment of opioid overdose
|